Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders

By Guico-Pabia C.J.   Jiang Q.   Ninan P.T.   Thase M.E.  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1815-1826

Informa Healthcare

Access to resources Recommend Favorite

P149: Interim analysis for sofosbuvir national treatment program in Egypt

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 94-94

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resell versus direct models in brand drug distribution

By Iacocca Kathleen   Zhao Yao   Fein Adam  

International Journal of Pharmaceutical and Healthcare Marketing, Vol. 7, Iss. 4, 2013-11 ,pp. : 324-340

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 219-226

John Wiley & Sons Inc

Access to resources Recommend Favorite

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

By Grima D.   Papaioannou A.   Thompson M.   Pasquale M.   Adachi J.  

Osteoporosis International, Vol. 19, Iss. 5, 2008-05 ,pp. : 687-697

Springer Publishing Company

Access to resources Recommend Favorite